Company Nkarta, Inc.

Equities

NKTX

US65487U1088

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:00 26/04/2024 BST 5-day change 1st Jan Change
6.87 USD +0.73% Intraday chart for Nkarta, Inc. -5.76% +4.09%

Business Summary

Nkarta, Inc. is a clinical-stage biopharmaceutical company advancing the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies for the treatment of patients with autoimmune diseases or hematologic malignancies. It is developing NKX019, a chimeric antigen receptor-natural killer (CAR NK) product candidate targeting the CD19 antigen and NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands. Both product candidates enable an on-demand, off-the-shelf approach involving scaled manufacturing to broaden patient access. Its NKX019 autoimmune program is based on the potential to eliminate the pathologic B cells that produce autoantibodies. Its NKX019 oncology program is based on the potential to treat a variety of B-cell malignancies by targeting the CD19 antigen that is reliably expressed on these types of cancerous cells. Its NKX101 program is designed to enhance the power of innate NK cell biology to detect and kill cancerous cells.

Number of employees: 150

Managers

Managers TitleAgeSince
Chief Executive Officer 64 31/01/18
Director of Finance/CFO - 04/07/23
Chief Tech/Sci/R&D Officer 61 31/08/16
Chief Tech/Sci/R&D Officer 55 31/03/18
Chief Tech/Sci/R&D Officer 46 31/05/20
Investor Relations Contact - 31/01/20
General Counsel 54 31/10/20

Members of the board

Members of the board TitleAgeSince
Director/Board Member 61 26/04/20
Chief Executive Officer 64 31/01/18
Director/Board Member 57 31/07/19
Chairman 47 31/07/15
Director/Board Member 49 31/07/19
Director/Board Member 47 31/01/20
Director/Board Member 42 27/03/22

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 70,191,295 66,573,185 ( 94.85 %) 0 94.85 %

Shareholders

NameEquities%Valuation
RA Capital Management LP
28.02 %
13,848,371 28.02 % 150 M $
RA Capital Management LP
15.79 %
7,805,129 15.79 % 84 M $
Boxer Capital LLC
8.919 %
4,407,350 8.919 % 48 M $
Samsara Biocapital LLC
7.625 %
3,768,035 7.625 % 41 M $
NEA Management Co. LLC
7.222 %
3,568,781 7.222 % 39 M $
Adage Capital Partners GP LLC
6.982 %
3,450,000 6.982 % 37 M $
Deerfield Management Co. LP (Private Equity)
6.880 %
3,400,000 6.880 % 37 M $
GSK PLC
6.376 %
3,150,732 6.376 % 34 M $
LSP Management Group BV
5.740 %
2,836,539 5.740 % 31 M $
Commodore Capital LP
5.525 %
2,730,000 5.525 % 30 M $

Company contact information

Nkarta, Inc.

1150 Veterans Boulevard

94080, South San Francisco

+

http://www.nkartatx.com
address Nkarta, Inc.(NKTX)